Influence of E. coli Strain Nissle 1917 (EcN) on Intestinal Gas Dynamics and Abdominal Sensation

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Digestive Diseases and Sciences

• Publication date

  2008-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s10620-007-9892-3PMID 17712634
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The probiotic Escherichia coli strain Nissle 1917 (EcN) stops acute diarrhoea in infants and toddlers

  2007cited by this paper
• [Maintaining remission of ulcerative colitis with the probiotic Escherichia Coli Nissle 1917 is as effective as with standard mesalazine].

  2006cited by this paper
• [Probiotic drug therapy with E. coli strain Nissle 1917 (EcN): results of a prospective study of the records of 3,807 patients].

  2006cited by this paper
• Relationship of abdominal bloating to distention in irritable bowel syndrome and effect of bowel habit.

  2006cited by this paper
• Probiotische Arzneimitteltherapie mit E. coli Stamm Nissle 1917 (EcN): Ergebnisse einer prospektiven Datenerhebung mit 3807 Patienten

  2006cited by this paper
• Antibiotics and probiotics in treatment of inflammatory bowel disease.

  2006cited by this paper
• Abdominal bloating.

  2005cited by this paper
• VSL#3: an analysis of basic and clinical contributions in probiotic therapeutics.

  2005cited by this paper
• The pathogenesis of bloating and visible distension in irritable bowel syndrome.

  2005cited by this paper
• Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine

  2004cited by this paper
• [Probiotics in inflammatory bowel disease: controlled trials and perspectives].

  2004cited by this paper
• Treatment of excessive intestinal gas

  2004cited by this paper
• Probiotiques et maladies inflammatoires chroniques de l'intestin : essais contrôlés et perspectives

  2004cited by this paper
• Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC)

  2003cited by this paper
• Gut flora in health and disease.

  2003cited by this paper
• A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea‐predominant irritable bowel syndrome

  2003cited by this paper
• Intestinal gas distribution determines abdominal symptoms

  2001cited by this paper
• Probiotics, prebiotics, and synbiotics--approaching a definition.

  2001cited by this paper
• Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome

  2001cited by this paper
• A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome

  2001cited by this paper
• Mechanisms of intestinal gas retention in humans: impaired propulsion versus obstructed evacuation.

  2001cited by this paper
• Reflex control of intestinal gas dynamics and tolerance in humans.

  2000cited by this paper
• Probiotics and intestinal inflammatory disorders in infants and children.

  2000cited by this paper
• Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome

  2000cited by this paper
• Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial.

  1999cited by this paper
• Intestinal gas dynamics and tolerance in humans.

  1998cited by this paper
• Double‐blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis

  1997cited by this paper
• The Relation of Passage of Gas and Abdominal Bloating to Colonic Gas Production

  1996cited by this paper
• Properties ofEscherichia coli strains of serotype O6

  1995cited by this paper
• [Treatment of chronic constipation with physiologic Escherichia coli bacteria. Results of a clinical study of the effectiveness and tolerance of microbiological therapy with the E. coli Nissle 1917 strain (Mutaflor)].

  1994cited by this paper
• Intestinal gas.

  1977cited by this paper
• Intestinal gas.

  1975cited by this paper
• Interpreting cardiac catheterization data. Part 2.

  1975cited by this paper
• Abdominal bloating.

  1952cited by this paper

• Robust performance of a live bacterial therapeutic chassis lacking the colibactin gene cluster

  2023cites this paper
• Gaz digestifs

  2017cites this paper
• Insights from 100 Years of Research with Probiotic E. Coli

  2016cites this paper
• Recombinant production of omega-3 fatty acids by probiotic Escherichia coli Nissle 1917.

  2015cites this paper
• [The role of Escherichia coli strain Nissle 1917 in the gastro-intestinal diseases].

  2014cites this paper
• Development of quorum-sensing-based genetic circuits that enable programmable functionalities in escherichia coli

  2014cites this paper
• Safety of Probiotics to Reduce Risk and Prevent or Treat Disease

  2011cites this paper
• Fermented milk containing Bifidobacterium lactis DN-173 010 improves gastrointestinal well-being and digestive symptoms in women reporting minor digestive symptoms: a randomised, double-blind, parallel, controlled study

  2009cites this paper
• The non-pathogenic Escherichia coli strain Nissle 1917 – features of a versatile probiotic

  2009cites this paper